AI and Gene Therapy as the Next Frontier

Effective new treatments are entering the clinic for uveitis.

The use of artificial intelligence (AI) and taking a ‘cross-sciences’ research approach holds the key to unlocking better future treatment pathways for uveitis...

Author: Priscilla Lynch

Improving Clinical Management for nAMD and DME

Global survey data identify barriers and opportunities.

Findings from global surveys conducted to understand the challenges associated with nAMD, DR, and DME management will provide a roadmap to practical policy and clinical practice solutions that could improve care delivery, treatment adherence, and patient outcomes...

Author: Cheryl Guttman Krader

Defining AMD Treatment Protocol

Treatments trending to fewer injections for better results.

Intravitreal injections are the gold standard for the treatment of exudative macular disorders such as neovascular AMD, DME, and RVO, granting a high intraocular concentration with a low systemic exposure. However, according to Luis Arias Barquet MD, PhD, some key questions still need to be answered...

Author: Timothy Norris

Neuroprotectant Treatment for MacTel Type 2

Intravitreal implant releasing ciliary neurotrophic factor found safe and effective in pivotal trials.

Sustained intraocular delivery of ciliary neurotrophic factor (CNTF) using NT-501 encapsulated cell therapy (revakinagene taroretcel) is safe and effective for treating macular telangiectasia (MacTel) type 2, suggest the results of two phase 3 clinical trials.

Author: Cheryl Guttman Krader

Targeting the Kallikrein-Kinin System to Treat DME

Novel oral plasma kallikrein inhibitor shows promise in early clinical trial.

Results of a phase 2a study investigating RZ402 treatment for diabetic macular oedema (DME) show that the novel, orally administered plasma kallikrein inhibitor (PKI) had a favourable safety profile and potential efficacy based on measured change in central subfield thickness (CST).

Author: Cheryl Guttman Krader

Faricimab VOYAGER Study

Real-world experience with faricimab for treatment-naïve nAMD and DME is underway.

Early results from VOYAGER—a global, prospective, non-interventional study evaluating outcomes of faricimab for treating naïve neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DME) in clinical practice—show improvements in functional and anatomical measures as well as no new safety concerns.

Author: Cheryl Guttman Krader

Discovering Prodygy and Nirvana

New gene-agnostic treatments for inheritable retinal disease.

A new gene-agnostic therapy called SPVN06 (SparingVision) has shown favourable safety and tolerability profiles in patients with retinitis pigmentosa in the Phase I/II PRODYGY clinical trial.

Author: Roibeard O’hEineachain

Effect of COVID-19 and Vaccine on Retinal Disease

Registry-based studies indicate risk for retinal vascular occlusions have not increased.

Multiple cases, case series, and cohort studies report the development of retinal disease after COVID-19 and COVID-19 vaccination, and knowledge that COVID-19 can cause vascular damage and coagulopathy provides biologic plausibility implicating the infection and vaccination in these events.

Author: Cheryl Guttman Krader

Real-World Faricimab nAMD Outcomes

First-year results promising for efficacy and extending treatment intervals.

Author: Howard Larkin

Tackling the Coming AMD Epidemic

Prevention through healthy diet may be key, but more research is needed.

Author: Howard Larkin